Home / Stock ratings / GLP-1, Obesity and Biotech Stocks / REGN
Stock rating · Pharmaceutical Preparations
Regeneron Pharmaceuticals Inc (REGN) Stock Rating & Analysis
As of October 7, 2026, MELANY rates Regeneron Pharmaceuticals Inc 72 out of 100 (Highest Conviction). Its highest factor score is earnings track record at 92, and its lowest is macro fit at 50.
MELANY ratingRated 2026-10-07REGN · composite score
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes treatments for eye disease, cardiovascular disease, cancer, and inflammation. Its marketed products include low-dose Eylea and Eylea HD for wet age-related macular degeneration and other eye diseases, Dupixent in immunology, Praluent for lowering LDL cholesterol, Libtayo in oncology, Kevzara for rheumatoid arthritis, and Lynozyfic for multiple myeloma. Its largest collaboration partners are Sanofi (Dupixent and others) and Bayer (Eylea).
Rating as of 2026-10-07 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
How REGN's rating has moved
- +2Past week, since Sep 30: score rose 2 points to 72.
- +3Past four weeks, since Sep 9: score rose 3 points to 72.
Weekly points: Sep 9: 69 · Sep 16: 70 · Sep 23: 71 · Sep 30: 70 · Oct 7: 72 (this page).
From MELANY's own dated rating record. A tier change is reported as a move between named tiers; the score carries the direction.
Why REGN scores 72/100
REGN's 8 factor scores run from 50 to 92, and 2 of them sit above its composite of 72. Here is how REGN breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- P/E 18.3x vs sector 22.0x median
- Forward P/E 12.0x, earnings growth accelerating
- PEG ratio 1.24 (< 1 = undervalued)
Margins, returns on capital, and balance-sheet strength.
- Gross margin 44%
Direction and relative strength of the recent share-price trend.
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
- Avg EPS beat +17%
- Earnings in 23 days (strong beat history)
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
- Earnings in 23 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How REGN compares
As of October 7, 2026, Regeneron Pharmaceuticals Inc is tied for 3rd of 20 in GLP-1, Obesity and Biotech Stocks, where the average score is 64.
Also ranked in Healthcare Stocks. All stock rating pages.
Key risks for REGN
- No specific company-level red flags detected, monitor macro regime changes
Sector and theme context
Regeneron Pharmaceuticals Inc sits in the Biotech (GLP-1 + innovation cluster) theme, which MELANY currently rates 61/100 for strength. Theme strength feeds REGN's momentum and catalyst factors above.
REGN trade plan (Pro)
MELANY has a full position plan for Regeneron Pharmaceuticals Inc: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates REGN
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Regeneron Pharmaceuticals Inc's 72/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about REGN
Is Regeneron Pharmaceuticals Inc (REGN) a buy?
As of 2026-10-07, MELANY rated Regeneron Pharmaceuticals Inc Highest Conviction with a composite score of 72/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Regeneron Pharmaceuticals Inc's MELANY score?
Regeneron Pharmaceuticals Inc (REGN) has a MELANY composite score of 72/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the REGN stock rating calculated?
MELANY scores REGN from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Regeneron Pharmaceuticals Inc stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Regeneron Pharmaceuticals Inc (REGN) Highest Conviction with a composite of 72/100 as of 2026-10-07. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the REGN stock price forecast?
MELANY does not publish price targets or forecasts for REGN. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 72/100 across eight factors for Regeneron Pharmaceuticals Inc, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is REGN stock overvalued or undervalued?
MELANY's valuation factor currently reads 68/100 for Regeneron Pharmaceuticals Inc, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives REGN's read.
What price should I buy REGN at?
Rather than chasing the current price, MELANY computes a smart entry zone for REGN: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying REGN stock?
The top risks MELANY currently flags for Regeneron Pharmaceuticals Inc: No specific company-level red flags detected, monitor macro regime changes. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Regeneron Pharmaceuticals Inc a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 72/100 for Regeneron Pharmaceuticals Inc, and earnings track record, at 92/100. The 72/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will REGN stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 57/100 for REGN right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this REGN rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-07. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores REGN continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, REGN included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.